Largeot et al. used FL3, a synthetic flavagline that acts as a prohibitin-binding drug, and used a multi-omic analysis on CLL patient samples and cell lines treated with FL3. The gene discussed is PHB1; the disease is B-cell chronic lymphocytic leukemia.